

Information about ordinary shares of QBiotech Group Limited as at 30 June 2022

Purpose

The purpose of this document is to provide information about the ordinary share capital of QBiotech Group Limited (the Company) as at 30 June 2022 to shareholders of the Company and their advisors.

Information as at 30 June 2022

- As at 30 June 2022 the Company had 487,756,371 ordinary shares on issue with all shares fully paid.
- The Company's ordinary shares were not listed in an open market as at 30 June 2022 or at any point during the year ended on that date.
- The Company has not performed a formal valuation of the Company as at 30 June 2022.

From time to time, the Company is required to calculate an estimated market value of the Company's shares for accounting and taxation purposes. The Company uses the weighted average transaction value of off-market share transactions for a period of 60 days leading up to the measurement date to calculate the estimated market value. The calculated value is then analysed against a historic trend and adjusted for any transactions which may have involved distressed sellers or non arms length transactions.

The weighted average transaction value of ordinary shares during the 60 days leading up to 30 June 2022 was \$1.172 per share.

Disclaimer

This document is not a valuation of ordinary shares in the Company or a valuation of the business conducted by the Company. Where an unlisted ordinary share is held privately by an individual or group of shareholders, applying the appropriate valuation method (or methods) may be complex.

The information in this document is general and does not constitute formal advice. The Company recommends seeking advice from a qualified accountant, professional valuation advisor or otherwise suitably qualified professional if you intend to rely upon any of the information provided for any purpose including accounting or tax purposes.

While the Company tries to ensure that the content of this document is accurate, adequate, and complete, it does not represent or warrant its accuracy, adequacy or completeness. The Company is not responsible for any loss suffered as a result of or in relation to the use of this document. To the extent permitted by law, the Company excludes any liability, including any liability for negligence, for any loss, including indirect or consequential damages arising from or in relation to the use of this document.

Information about ordinary shares of QBiotics Group Limited as at 30 June 2022

Purpose

The purpose of this document is to provide information about the ordinary share capital of QBiotics Group Limited (the Company) as at 30 June 2022 to shareholders of the Company and their advisors.

Information as at 30 June 2022

- As at 30 June 2022 the Company had 487,756,371 ordinary shares on issue with all shares fully paid.
- The Company's ordinary shares were not listed in an open market as at 30 June 2022 or at any point during the year ended on that date.
- The Company has not performed a formal valuation of the Company as at 30 June 2022.

From time to time, the Company is required to calculate an estimated market value of the Company's shares for accounting and taxation purposes. The Company uses the weighted average transaction value of off-market share transactions for a period of 60 days leading up to the measurement date to calculate the estimated market value. The calculated value is then analysed against a historic trend and adjusted for any transactions which may have involved distressed sellers or non arms length transactions.

The weighted average transaction value of ordinary shares during the 60 days leading up to 30 June 2022 was \$1.172 per share.

Disclaimer

This document is not a valuation of ordinary shares in the Company or a valuation of the business conducted by the Company. Where an unlisted ordinary share is held privately by an individual or group of shareholders, applying the appropriate valuation method (or methods) may be complex.

The information in this document is general and does not constitute formal advice. The Company recommends seeking advice from a qualified accountant, professional valuation advisor or otherwise suitably qualified professional if you intend to rely upon any of the information provided for any purpose including accounting or tax purposes.

While the Company tries to ensure that the content of this document is accurate, adequate, and complete, it does not represent or warrant its accuracy, adequacy or completeness. The Company is not responsible for any loss suffered as a result of or in relation to the use of this document. To the extent permitted by law, the Company excludes any liability, including any liability for negligence, for any loss, including indirect or consequential damages arising from or in relation to the use of this document.